Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

Cancer Immunology Immunotherapy

Volumn 44, Issue 3, 1997, Pages 157-164

  Wersall P ^a   Ohlsson, I ^a   Biberfeld, P ^a   Collins, V P ^a   Von Krusenstjerna, S ^a   Larsson, S ^a   Mellstedt, H ^a,b   Boethius, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Epidermal growth factor; Glioma; Immunotherapy; Murine monoclonal antibody

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ANTIBODY; LEUKOCYTE ELASTASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLERGY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTRATUMORAL DRUG ADMINISTRATION; MALE; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEINURIA; TUMOR NECROSIS;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE;

EID: 0030947678     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050368     Document Type: Article

References (27)

1. Adams DO, Hall T, Steplewski Z, Koprowski H (1994) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotype containing increased numbers of macrophages activated for distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci USA 81: 3506
2. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 52: 121
3. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P (1991) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22: 225
4. Estaban JM, Colcher D, Sugerbaker P (1987) Quantitative and qualitative aspects of rudiolocalisation in colon cancer patients of intravenously administered MoAb B72.3. Int J Cancer 39: 50
5. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wigzell H, Mellstedt H (1995) Tumor regression in monoclonal antibody treated patients correlates with the presence of anti-idiotype reactive T-lymphocytes. Cancer Res 55: 1824
6. Garcia CF, Lowder J, Meeker TC, Bindl J, Levy R, Varnker RA (1985) Differencies in "host infiltrates" among lymphoma patients treated with anti-idiotypic antibodies: Correlations with treatment response. J Immunol 135: 4252
7. Hendler FJ, Ozanne BW (1984) Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74: 647
8. Kaplan RS (1993) Supratentorial malignant gliomas: risk patterns and therapy. J Natl Cancer Inst 85: 690
9. 131I-coupled to MoAbs as therapeutic agents for neuroectodermally derived tumours: fact or fiction. Cancer Drug Delivery 3: 25
10. Kemshead JT, Papanastassiou V, Coakham HB, Pizer BL (1992) Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer 28: 511
11. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dörken B, Maldenhauer G (1988) Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 167: 345
12. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H (1984) Expression of epidermal growth factors in human brain tumors. Cancer Res 44: 753
13. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J (1985) Amplification, enhanced expression, and possible rearrangement of EGF receptor gene in primary brain tumours of glial origin. Nature 313: 144
14. Mason DY, Bell JJ, Christensson B, Biberfeld P (1980) An immunohistological study of human lymphoma. Clin Exp Immunol 40: 235
15. Masucci G, Ragnhammar P, Wersäll P, Mellstedt H (1990) Granulocyte- monocyte colony-slimulating-factor augments the interleukin-2 induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb17-1A). Cancer Immunol Immunother 31: 231
16. Murthy U, Basu A, Rodeck U, Herlyn M, Ross A, Das M (1987) Domain-specificity and antagonistic properties of a new monoclonal antibody to the EGF-receptor. Arch Biochem Biophys 252: 549
17. Neal DE, Marsh C, Benett MK, Abel PD, Hall RR, Sainsbury JRC, Harris AL (1985) Epidermal-growth-factor receptors in human bladder cancer; Comparison of invasive and superficial tumours. Lancet 1: 366
18. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1: 368
19. Ragnhammar P, Frödin J-E, Hjelm A-L, Fagerberg J, Wersäll P, Lindemalm C, Nilsson B, Fox K, Magnusson I, Ewerth S, Thor K, Secher E, Mellstedt H (1995) Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma. Int J Oncol 7: 1049
20. Rajan B, Ross G, Lim C, Ashley SD, Goode D, Traish D, Brada M (1994) Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosurea chemotherapy. Eur J Cancer 30A: 1809
21. Riva P, Arista A, Tison V, Sturiale C, Franceshia G, Spinelli A, Riva N, Casi M, Moscatelli G, Frattarelli M (1994) Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer 73: 1076
22. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z, Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: mmunologically mediated and effector cell-independent effects. Cancer Res 47: 3692
23. Rodeck U, Williams N, Murthy U, Herlyn M (1990) Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF-TGF-α. J Cell Biochem 44: 69
24. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL (1985) Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1(8425): 364
25. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre J-Y (1996) Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD55900) in patients with recurrent malignant gliomas. Eur J Cancer 32A: 636
26. Takahashi H, Belser PH, Atkinson BF, Sela BA, Ross AH, Biegel J, Emunuel B, Sutton L, Koprowski H, Herlyn D (1990) Monoclonal antibody-dependent, cell-mediated cytotoxicity against human malignant gliomas. Neurosurgery 27: 97
27. Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AO (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites. J Clin Oncol 10: 1636